Subsequent Events (Details) (USD $)	6 Months Ended		1 Months Ended	6 Months Ended	7 Months Ended	1 Months Ended		6 Months Ended	1 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jul. 31, 2013 Equity Offering [Member]	Jun. 30, 2013 Equity Offering [Member]	Jul. 31, 2013 Equity Offering [Member]	Jul. 31, 2013 Subsequent Event [Member]	Aug. 07, 2013 Subsequent Event [Member]	Jun. 30, 2013 Subsequent Event [Member]	Jul. 31, 2013 Subsequent Event [Member] Contingent On Merger Agreement [Member]	Jul. 31, 2013 Subsequent Event [Member] Superior Proposal Termination Contingency [Member]	Jul. 31, 2013 Subsequent Event [Member] Transaction Event Termination Contingency [Member]	Jul. 31, 2013 Subsequent Event [Member] Theraclone [Member] Contingent On Merger Agreement [Member]	Jul. 31, 2013 Subsequent Event [Member] PharmAthene [Member]	Jul. 31, 2013 Subsequent Event [Member] PharmAthene [Member] Contingent On Merger Agreement [Member]	Jul. 31, 2013 Subsequent Event [Member] PharmAthene [Member] Maximum [Member]	Jul. 31, 2013 Subsequent Event [Member] Post-Closing Lock-up Agreements [Member]	Jul. 31, 2013 Subsequent Event [Member] Post-Closing Lock-up Agreements [Member] Lock-up Scenario One [Member]	Jul. 31, 2013 Subsequent Event [Member] Post-Closing Lock-up Agreements [Member] Lock-up Scenario Two [Member]	Jul. 31, 2013 Subsequent Event [Member] Post-Closing Lock-up Agreements [Member] Lock-up Scenario Three [Member]	Jul. 31, 2013 Subsequent Event [Member] Theraclone Voting Agreement [Member]	Jul. 31, 2013 Subsequent Event [Member] PharmAthene Voting Agreement [Member]
Subsequent Event [Line Items]
Percentage of merger consideration issuable to the stockholders						5.00%							5.00%
Number of shares sold				2,777,336				1,105,837
Amount remaining available under controlled equity offering arrangement				$ 10,400,000			$ 8,600,000
Proceeds from issuance of common stock, net of issuance costs	3,810,403	38,983	500,000		4,200,000		1,700,000
Percentage of interests in fully dilutive equity following the consumation of the merger									50.00%
Break up fee										3,500,000	4,500,000
Aggregate amount of contingent indemnification claims, minimum													1,000,000
Merger agreement, not to exceed amount for reimbursement of expenses to Theraclone.															1,000,000
Committed capital, completion of merger condition						$ 8,000,000
Maximum exercise of appraisal rights percentage allowed of PharmAthene's stockholders, completion of merger condition						5.00%
Minimum percentage of outstanding shares owned of Theraclone's capital stock																5.00%
Merger agreement, percentage of board approval to remove CEO						66.66%
Stockholders' aggregate approximate percentage of outstanding shares held in Theraclone																75.00%
Percentage of outstanding shares owned																					7.50%
Stockholders aggregate approximate percentage of outstanding shares																				75.00%
Threshold price per share qualifying as fully diluted equity						$ 2.50
Number of members on board of directors									9			4		5
Threshold percentage of capital stock held									5.00%
Threshold period of time required to remove CEO						30 days
Preferred stock, conversion basis																				1:1
Stock acquired percentage allowablefor sale																	33.00%	66.00%	100.00%
Maximum period of time after substantive decision rendered board may deem merger unequal						20 days
Merger agreement outside termination date extension						60 days